Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies to treat kidney diseases.

The US FDA has approved Viatris' Ryzumvi (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults.

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.

Zealand Pharma and AI-centric biotech Generate Biomedicines have teamed up to develop protein-based therapeutics for obesity and other metabolic diseases in a deal rising to $1.2b ...

Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of AD, including the clinical progression of its lead candidate, ...

Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.

The MHRA’s new 2030 strategy plans to make drug and device regulation more efficient and patient centric by using technologies like AI.

The duo of funds will support companies across the biopharma, healthcare technology, diagnostics and medical device disciplines.

Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications.

Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies, is aiming for a $135m initial public offering (IPO) to fund clinical ...

Revolution’s Rasonque has been called a turning point for pancreatic cancer patients, nearly doubling median overall survival in the second-line setting.

CRL has collaborated with Australian biotechnology firm Magellan Stem Cells to advance the development and clinical progress of Magellan's regenerative medicine candidate, Zelestrocel.